Skip to Content

Smith & Nephew PLC

SN.: XLON (GBR)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
GBX 6,769.00YwbqvhmCqrjfbvrg

Smith & Nephew Racks Up Consistent Operational Gains

Business Strategy and Outlook

Impressive innovation has allowed Smith & Nephew to carve out a slice of the orthopedic, sports medicine, and wound care markets. Though the company is substantially smaller than the dominant orthopedic competitors, it has punched above its weight in terms of introducing meaningful innovation with its hip implants and knee replacements. For example, its Oxinium technology has demonstrated lower rates of revisions in hip replacements. The firm has also commercialized Regeneten, an implant that facilitates the growth of tendon-like tissue.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of SN. so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center